Proton therapy for lung cancer

Thoracic Cancer

Volumn 3, Issue 2, 2012, Pages 109-116

  Nichols, Romaine C ^a   Henderson, Randal H ^a   Huh, Soon ^a   Flampouri, Stella ^a   Li, Zuofeng ^a   Bajwa, Abubakr A ^b   D'Agostino, Harry J ^b   Pham, Dat C ^b   Mendenhall, Nancy P ^a   Hoppe, Bradford S ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Literature review; Lung cancer; Proton therapy; Radiation therapy; Thoracic tumors

Indexed keywords

EID: 84868135301     PISSN: 17597706     EISSN: 17597714     Source Type: Journal    
DOI: 10.1111/j.1759-7714.2011.00098.x     Document Type: Review

References (25)

1. Chang JY, Zhang X,Wang X et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006; 65: 1087- 96.
2. Georg D,Hillbrand M, StockM,Dieckmann K, Potter R. Can protons improve SBRT for lung lesions? Dosimetric considerations. Radiother Oncol 2008; 88: 368-75.
3. Wang C,Nakayama H, Sugahara S, Sakae T, Tokuuye K. Comparisons of dose-volume histograms for proton-beam versus 3-D conformal x-ray therapy in patients with stage I non-small cell lung cancer. Strahlenther Onkol 2009; 185: 231-4.
4. Macdonald OK, Kruse JJ,Miller JM et al. Proton beam radiotherapy versus three-dimensional conformal stereotactic body radiotherapy in primary peripheral, early-stage non-small-cell lung carcinoma: a comparative dosimetric analysis. Int J Radiat Oncol Biol Phys 2009; 75: 950-8.
5. Hoppe BS,Huh S, Flampouri S et al. Double-scattered proton-based stereotactic body radiotherapy for stage I lung cancer: a dosimetric comparison with photon-based stereotactic body radiotherapy. Radiother Oncol [Comparative Study] 2010; 97: 425-30.
6. Kadoya N,Obata Y, Kato T et al. Dose-volume comparison of proton radiotherapy and stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011; 79: 1225-31.
7. Register SP, Zhang X,Mohan R, Chang JY. Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011; 80: 1015-22.
8. Chang JY, Komaki R,Wen HY et al. Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2011; 80: 1350-7.
9. Nakayama H, Sugahara S, TokitaMet al. Proton beam therapy for patients with medically inoperable stage I non-small-cell lung cancer at the University of Tsukuba. Int J Radiat Oncol Biol Phys 2010; 78: 467-71.
10. Iwata H,Murakami M, Demizu Y et al. High-dose proton therapy and carbon-ion therapy for stage I nonsmall cell lung cancer. Cancer 2010; 116: 2476-85.
11. Hata M, Tokuuye K, Kagei K et al. Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study. Int J Radiat Oncol Biol Phys 2007; 68: 786-93.
12. Nihei K,Ogino T, Ishikura S, Nishimura H. High-dose proton beam therapy for Stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006; 65: 107-11.
13. Shioyama Y, Tokuuye K, Okumura T et al. Clinical evaluation of proton radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2003; 56: 7-13.
14. Bush DA, Slater JD, Bonnet R et al. Proton-beam radiotherapy for early-stage lung cancer. Chest 1999; 116: 1313-19.
15. Zhang X, Li Y, Pan X et al. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys 2010; 77: 357-66.
16. Nichols RC,Huh SN,Henderson RH et al. Proton radiation therapy offers reduced normal lung and bone marrow exposure for patients receiving dose-escalated radiation therapy for unresectable stage III non-small-cell lung cancer: a dosimetric study. Clin Lung Cancer 2011; 12: 252-7.
17. Nichols RC,Huh SH,Hoppe BS et al. Protons safely allow coverage of high-risk nodes for patients with regionally advanced non-small-cell lung cancer. Technol Cancer Res Treat 2011; 10: 317-22.
18. Sejpal S, Komaki R, Tsao A et al. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer 2011; 117: 3004-13.
19. Chang JY, Komaki R, Lu C et al. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer 2011 Mar 22; doi: 10.1002/cncr.26080; [Epub ahead of Print].
20. Hoppe BS, Flampouri S, Pham D et al. Technique and early outcomes of proton therapy with concurrent chemotherapy for lung cancer. Clin Lung Cancer 2010 (in press).
21. Hui Z, Zhang X, Starkschall G et al. Effects of interfractional motion and anatomic changes on proton therapy dose distribution in lung cancer. Int J Radiat Oncol Biol Phys 2008; 72: 1385-95.
22. Shi W, Flampouri S, HsiWet al. Tumor shrinkage during proton-based chemoradiation for non-small-cell lung cancer may necessitate adaptive replanning during treatment. J Hong Kong Coll Radiol 2011; 14: 190-4.
23. Grutters JP, Pijls-Johannesma M, Ruysscher DD et al. The cost-effectiveness of particle therapy in non-small cell lung cancer: exploring decision uncertainty and areas for future research. Cancer Treat Rev 2010; 36: 468-76.
24. Peeters A, Grutters JP, Pijls-Johannesma M et al. How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons. Radiother Oncol 2010; 95: 45-53.
25. Truffer CJ, Keehan S, Smith S et al. Health spending projections through 2019: the recession's impact continues. Health Aff 2010; 29: 522-9.